Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 10 » Issue 1

Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease

Authors Nishijima Y, Minami S, Yamamoto S, Ogata Y, Koba T, Futami S, Komuta K

Received 1 November 2014

Accepted for publication 26 December 2014

Published 27 February 2015 Volume 2015:10(1) Pages 439—444

DOI https://doi.org/10.2147/COPD.S76836

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Richard Russell

Yu Nishijima,1,* Seigo Minami,1,* Suguru Yamamoto,1 Yoshitaka Ogata,1 Taro Koba,1,2 Shinji Futami,1 Kiyoshi Komuta1

1Department of Respiratory Medicine, Osaka Police Hospital, Tennoji-ku, Osaka, Japan; 2Department of Internal Medicine, National Hospital Organization, Kinki-Chuo Chest Medical Center, Kita-ku, Sakai, Osaka, Japan

*These authors contributed equally to this work

Background: Indacaterol, a once-daily, long-acting ß2-agonist, may improve not only respiratory function, dyspnea symptoms, and quality of life, but also physical activity for patients with chronic obstructive pulmonary disease (COPD). This study aimed to evaluate the effect of 12-week indacaterol therapy on daytime physical activity in patients with untreated COPD.
Methods: The subjects were stable and untreated COPD outpatients with a percent predicted forced expiratory volume in 1 second (%FEV1) below 80%. Baseline assessments included clinical assessment, respiratory function testing, arterial blood gas analysis, the COPD assessment test (CAT™), and the Medical Outcomes Study 36-Item Short-Form Health Survey, Japanese version 2 (SF-36v2®). Patients underwent monitoring by uniaxial accelerometer before and after 12 weeks once-daily inhalation of indacaterol 150 µg/day.
Results: Eighteen patients were evaluable. Patient characteristics included a mean age of 74.2 years, and three patients were current smokers. Indacaterol improved mean (± standard deviation [SD]) %FEV1 from 55.2% (±17.9%) to 61.0% (±17.3%) (P=0.003), CAT scores from 16.4 (±10.2) points to 12.4 (±8.2) points (P=0.04), some scales of the SF-36v2 (physical component summary, 41.6±9.7 points to 45.1±7.9 points, P=0.03), and number of daily steps (3,311.5±2,103.3 steps/day to 3,841.8±2,096.8 steps/day, P=0.02), but did not affect daily energy expenditure (85.0±77.2 kcal change to 90.9±56.8 kcal, P=0.29) or exercise duration of an intensity of level 1 or more (36.4±23.9 minutes increase to 40.8±21.6 minutes, P=0.12).
Conclusion: Twelve weeks of indacaterol improved respiratory function and quality of life, but did not significantly affect physical activity in patients with moderate-to-severe COPD.

Keywords: indacaterol, long-acting ß2-agonist, chronic obstructive pulmonary disease, physical activity, uniaxial accelerometer


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Outcomes and prognostic factors of chemotherapy for patients with locally advanced or metastatic pulmonary squamous cell carcinoma

Minami S, Ogata Y, Ihara S, Yamamoto S, Komuta K

Lung Cancer: Targets and Therapy 2016, 7:99-110

Published Date: 24 August 2016

Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer

Minami S, Ogata Y, Ihara S, Yamamoto S, Komuta K

Lung Cancer: Targets and Therapy 2016, 7:35-44

Published Date: 5 April 2016

Combination chemotherapy of gemcitabine and vinorelbine for pretreated non-small- cell lung cancer: a retrospective study

Minami S, Ogata Y, Yamamoto S, Komuta K

Lung Cancer: Targets and Therapy 2015, 6:83-90

Published Date: 25 September 2015

Readers of this article also read:

Home-based pulmonary rehabilitation improves clinical features and systemic inflammation in chronic obstructive pulmonary disease patients

Nascimento ESP, Sampaio LMM, Peixoto-Souza FS, Dias FD, Gomes ELFD, Greiffo FR, Ligeiro de Oliveira AP, Stirbulov R, Vieira RP, Costa D

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:645-653

Published Date: 23 March 2015

Functional capacity, physical activity, and quality of life in hypoxemic patients with chronic obstructive pulmonary disease

Saglam M, Vardar-Yagli N, Savci S, Inal-Ince D, Calik-Kutukcu E, Arikan H, Coplu L

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:423-428

Published Date: 26 February 2015